Literature DB >> 33715207

Polyfunctionality of the CXCR4/CXCL12 axis in health and disease: Implications for therapeutic interventions in cancer and immune-mediated diseases.

C Britton1, M C Poznansky1, P Reeves1,2.   

Abstract

Historically the chemokine receptor CXCR4 and its canonical ligand CXCL12 are associated with the bone marrow niche and hematopoiesis. However, CXCL12 exhibits broad tissue expression including brain, thymus, heart, lung, liver, kidney, spleen, and bone marrow. CXCR4 can be considered as a node which is integrating and transducing inputs from a range of ligand-receptor interactions into a responsive and divergent network of intracellular signaling pathways that impact multiple cellular processes such as proliferation, migration, and stress resistance. Dysregulation of the CXCR4/CXCL12 axis and consequent fundamental cellular processes, are associated with a panoply of disease. This review frames the polyfunctionality of the receptor at a molecular, physiological, and pathophysiological levels. Transitioning our perspective of this axis from a single gene/protein:single function model to a polyfunctional signaling cascade highlights the potential for finer therapeutic intervention and cautions against a reductionist approach.
© 2020 Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  GPCR; chemokine; therapeutics

Year:  2021        PMID: 33715207     DOI: 10.1096/fj.202001273R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  8 in total

Review 1.  CXCR4 as a novel target in immunology: moving away from typical antagonists.

Authors:  Birgit Caspar; Pietro Cocchiara; Armelle Melet; Kristof Van Emelen; Annegret Van der Aa; Graeme Milligan; Jean-Philippe Herbeuval
Journal:  Future Drug Discov       Date:  2022-07-19

2.  Metformin counteracts stimulatory effects induced by insulin in primary breast cancer cells.

Authors:  Domenica Scordamaglia; Francesca Cirillo; Marianna Talia; Maria Francesca Santolla; Damiano Cosimo Rigiracciolo; Lucia Muglia; Azzurra Zicarelli; Salvatore De Rosis; Francesca Giordano; Anna Maria Miglietta; Ernestina Marianna De Francesco; Veronica Vella; Antonino Belfiore; Rosamaria Lappano; Marcello Maggiolini
Journal:  J Transl Med       Date:  2022-06-07       Impact factor: 8.440

3.  miR-1273h-5p suppresses CXCL12 expression and inhibits gastric cancer cell invasion and metastasis.

Authors:  Yi-Chen Wang; Song Lu; Xiao-Jiang Zhou; Li Yang; Ping Liu; Lan Zhang; Yuan Hu; Xian-Zhe Dong
Journal:  Open Med (Wars)       Date:  2022-05-16

Review 4.  The Serine Protease CD26/DPP4 in Non-Transformed and Malignant T Cells.

Authors:  Guranda Chitadze; Ulrike Wehkamp; Ottmar Janssen; Monika Brüggemann; Marcus Lettau
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

5.  Investigating CXCR4 expression of tumor cells and the vascular compartment: A multimodal approach.

Authors:  Marta Braga; Chee Hau Leow; Javier Hernandez Gil; Jin H Teh; Laurence Carroll; Nicholas J Long; Meng-Xing Tang; Eric O Aboagye
Journal:  PLoS One       Date:  2021-11-18       Impact factor: 3.240

6.  Role of endothelial CXCR4 in the development of aortic valve stenosis.

Authors:  Anna Winnicki; James Gadd; Vahagn Ohanyan; Gilbert Hernandez; Yang Wang; Molly Enrick; Hannah McKillen; Matthew Kiedrowski; Dipan Kundu; Karlina Kegecik; Marc Penn; William M Chilian; Liya Yin; Feng Dong
Journal:  Front Cardiovasc Med       Date:  2022-09-06

7.  Interaction between mesenchymal stem cells and myoblasts in the context of facioscapulohumeral muscular dystrophy contributes to the disease phenotype.

Authors:  Ekaterina Kiseleva; Olesya Serbina; Anna Karpukhina; Vincent Mouly; Yegor S Vassetzky
Journal:  J Cell Physiol       Date:  2022-05-27       Impact factor: 6.513

8.  Engagement of the CXCL12-CXCR4 Axis in the Interaction of Endothelial Progenitor Cell and Smooth Muscle Cell to Promote Phenotype Control and Guard Vascular Homeostasis.

Authors:  Sebastian F Mause; Elisabeth Ritzel; Annika Deck; Felix Vogt; Elisa A Liehn
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.